Открытый доступ
Доступ платный или только для подписчиков
Вопросы разработки генотерапевтических лекарственных препаратов
Аннотация
Ключевые слова
Ссылки
Walsh C. E. Gene therapy progress and prospects: Gene therapy for the hemophilias / Gene Ther. 2003. V. 10. № 12. P. 999 – 1003.
Van Deutekom J. C. T., Van Ommen G. B. Advances in Duchenne muscular dystrophy gene therapy / Nat. Rev. Genet. 2003. V. 4. № 10. P. 774 – 783.
Ferrari S., Geddes D. M., Alton E. W. F. W. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis / Adv. Drug Deliv. Rev. 2002. V. 54. № 11. P. 1373 – 1393.
O’Connor T., Crystal R. Genetic medicines: treatment strategies for hereditary disorders / Nat. Rev. Genet. 2006. V. 7. № 4. P. 1 – 76.
Bunnell B. A., Morgan R. A. Gene therapy for infectious diseases / Clin. Microbiol. Rev. 1998. V. 11. № 1. P. 42 – 56.
Dzau V. J. et al. Current perceptions of cardiovascular gene therapy / Am J Cardiol. 2003. Vol. 9149. № 3. P. 18 – 23.
Tuszynski M. H. Growth-factor gene therapy for neurodegenerative disorders / Lancet Neurol. 2002. V. 1. № 1. P. 51 – 57.
Vile R. G., Russell S. J., Lemoine N. R. Cancer gene therapy: hard lessons and new courses / Gene Ther. 2000. V. 7. № 1. P. 2 – 8.
Chen C. et al. Molecular characterization of adeno-associated viruses infecting children / J. Virol. 2005. V. 79. № 23. P. 14781 – 14792.
Li C. et al. Adeno-associated virus vectors: potential applications for cancer gene therapy / Cancer Gene Ther. 2005. V. 12. № 12. P. 913 – 925.
Cutroneo K. R. Gene therapy for tissue regeneration / J. Cell Biochem. 2003. V. 88. № 2. P. 418 – 425.
Wood K., Fry J. Gene therapy: potential applications in clinical transplantation. / Expert Rev. Mol. Med. 1999. P. 1 – 20.
Baum C. et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors / Hum. Gene Ther. 2006. V. 17. № 3. P. 253 – 263.
Bessis N., Garciacozar F. J., Boissier M. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms / Gene Ther. 2004. 11. S10 – S17.
Waehler R., Russell S. J., Curiel D. T. Engineering targeted viral vectors for gene therapy / Nat. Rev. Genet. 2007. V. 8. № 8. P. 573 – 587.
Thomas C. E., Ehrhardt A., Kay M. A. Progress and problems with the use of viral vectors for gene therapy / Nat. Rev. Genet. 2003. V. 4. № 5. P. 346 – 358.
Bouard D., Cosset F. Viral vectors: from virology to transgene expression / Br. J. Pharmacol. 2009. V. 157. № 2. P. 153 – 165.
Ramamoorth M., Narvekar A. Non viral vectors in gene therapy — an overview / J. Clin. Diagn. Res. 2015. V. 9. № 1. P. 1 – 6.
San H. et al. Safety and short-term toxicity of a nov el cationic lipid formulation for human gene therapy / Hum. Gene Ther. 1993. V. 4. № 6. P. 781 – 788.
Morishita R. et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease / Hypertension. 2004. V. 44. № 2. P. 203 – 209.
Dubensky T. J., Sauter S. Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer / Meth. Mol. Med. 2003. V. 76. P. 309 – 330.
Mintzer M. A., Simanek E. E. Nonviral vectors for gene delivery / Chem. Rev. 2009. V. 109. № 2. P. 259 – 302.
Pack D. W. et al. Design and development of polymers for gene delivery / Nat. Rev. Drug Discov. 2005. V. 4. № 7. P. 581 – 593.
Wolff J. et al. Direct gene transfer into mouse muscle in vivo / Science. 1990. V. 247. № 4949. Pt 1. P. 1465 – 1468.
Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake / Pharm. Res. 1995. V. 12. № 6. P. 825 – 830.
Felgner J. H. et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations / J. Biol. Chem. 1994. V. 269. № 4. P. 2550 – 2561.
Gao X., Huang L. Cationic liposome-mediated gene transfer / Gene Ther. 1995. V. 35. № 3. P. 1027 – 1036.
Khalil I. A. et al. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery / Pharmacol. Rev. 2006. V. 58. № 1. P. 32 – 45.
Lechardeur D. et al. Metabolic instability of plasmid DNA in the cytosol: A potential barrier to gene transfer / Gene Ther. 1999. V. 6. № 4. P. 482 – 497.
Dowty M. E. et al. Plasmid DNA entry into postmitotic nuclei of primary rat myotubes / Proc. Natl. Acad. Sci. USA. 1995. V. 92. № 10. P. 4572 – 4576.
Luby-Phelps K. et al. Hindered diffusion of inert tracer particles in the cytoplasm of mouse 3T3 cells / Proc. Natl. Acad. Sci. USA. 1987. V. 84. № 14. P. 4910 – 4913.
Mislick K. A., Baldeschwieler J. D. Evidence for the role of proteoglycans in cation-mediated gene transfer / Proc. Natl. Acad. Sci. USA. 1996. V. 93. № 22. P. 12349 – 12354.
Erbacher P. et al. Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA / Lactosylated polylysine complexes / Exp. Cell Res. 1996. V. 225. № 1. P. 186 – 194.
Bonner W. M. Protein migration into nuclei. I. Frog oocyte nuclei in vivo accumulate microinjected histones, allow entry to small proteins, and exclude large proteins / J. Cell Biol. 1975. V. 64. № 2. P. 421 – 430.
Featherstone C., Darby M. K., Gerace L. A Monoclonal antibody against the nuclear pore complex inhibits nucleocytoplasmic transport of protein and RNA in vivo / J. Cell Biol. 1988. V. 107. № 4. P. 1289 – 1297.
Lukacs G. L. et al. Size-dependent DNA mobility in cytoplasm and nucleus / J. Biol. Chem. 2000. V. 275. № 3. P. 1625 – 1629.
Sebesty?n M. et al. DNA vector chemistry: the covalent attachment of signal peptides to plasmid DNA / Nat. Biotechnol. 1998. V. 16. № 1. P. 80 – 85.
Miller A. M., Dean D. A. Tissue-specific and transcription factor-mediated nuclear entry of DNA / Adv. Drug Deliv. Rev. Elsevier B. V., 2009. V. 61. № 7 – 8. P. 603 – 613.
Wilke M. et al. Efficacy of a peptide-based gene delivery system depends on mitotic activity / Gene Ther. 1996. V. 3. № 12. P. 1133 – 1142.
Brunner S. et al. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus / Gene Ther. 2000. V. 7. № 5. P. 401 – 407.
EMA. Directive 2001/83/EC of the European Parliament and of the Council [Electronic resource]. 2001. URL: http://bit.ly/2OSmGEK.
FDA. Guidance for Industry: Gene Therapy Clinical Trials — Observing Subjects for Delayed Adverse Events [Electronic resource]. 2006. URL: http:// bit.ly/2PZjZO3.
?1047? Gene Therapy Products / US Pharmacopeia 38 NF. 2015.
SFDA. Points to Consider for Human Gene Therapy and Product Quality Control State Food and Drug Administration of China / BioPharm Int. 2004. P. 1 – 4.
Миронов А. и др. Состояние и перспективы развития генотерапии в России / Вестн. Росздравнадзора. 2011. № 4. С. 56 – 60.
Супотницкий М. В. и др. Особенности доклинических исследований на этапе разработки невирусных векторных конструкций, предназначенных для целей генной терапии / Ведом. НЦ экспертизы средств мед. примен. 2014. № 3. С. 30 – 38.
EMA. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2015. V. 44. March. P. 1 – 42.
EMEA. Summary of product characteristics — Glybera. 2012.
Vatsan R. S. Summary Basis for Regulatory Action — IMLYGIC. 2015.
Liebert M. A. Current status of Gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers / Gene Med. 2005. V. 16. № 9. P. 1016 – 1027.
Rivera V. M. et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer / Blood. 2005. V. 105. № 4. P. 1424 – 1430.
Wang L. et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy / Blood. 2005. V. 105. № 8. P. 3079 – 3086.
Xiao X., Li J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector / J. Virol. 1996. V. 70. № 11. P. 8098 – 8108.
Jiang H. et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B / Mol. Ther. 2006. V. 14. № 3. P. 452 – 455.
Walsh G. Pharmaceutical Biotechnology. The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England: John Wiley & Sons Ltd, 2007.
Будыльская Т. В. и др. Фармацевтическая разработка ГЛФ биофармацевтических препаратов для генной терапии / Разраб. и рег. лек. средств. 2016. Т. 1. № 14.С. 74 – 85.
Ссылки
- Ссылки не определены.
** ** ** ** ** **
ISSN: 2073-8099
** ** ** ** ** **
Подписаться на наши издания Вы можете через почтовые каталоги Объединенный каталог «Пресса России» «Урал Пресс», «Ивис», «Прессинформ» и «Профиздат».
Наши партнеры:
iIPhEB - Международная выставка и форум по фармацевтике и биотехнологиям, 2–4 апреля 2024